Taysha Gene Therapies Prices $200M Public Offering at Discount, Funds Rett Syndrome Program
TSHA has more than doubled off its 52-week low of $2.25 on elevated volume (4.3× avg).
Summary
Taysha Gene Therapies priced a $200 million public offering of common stock and pre-funded warrants at a discount, aiming to fund the development and commercial launch of its lead Rett syndrome gene therapy, TSHA-102, and extend its cash runway.
Key Events · Financing and Capital Events · TSHA
-
Public Offering Priced
Taysha Gene Therapies finalized the pricing of its public offering, selling 32,500,001 shares of common stock at $6.00 per share and pre-funded warrants to purchase up to 833,333 shares at $5.999 per warrant.
-
Significant Dilution
The offering, including the underwriters' option, could result in the issuance of up to 38,333,334 new shares, representing approximately 13.3% dilution based on shares outstanding as of March 31, 2026.
-
Discounted Pricing
The offering price of $6.00 per share is at a discount to the last reported sale price of $6.94 on June 24, 2026, and today's price of $6.21.
-
Capital for TSHA-102 Development
The estimated net proceeds of $187.4 million (or up to $215.6 million if the underwriters' option is fully exercised) will fund regulatory, manufacturing, and anticipated commercial launch of TSHA-102 for Rett syndrome, extending the cash runway into the second half of 2028.
Analysis · TSHA · Life Sciences
Taysha Gene Therapies has finalized the pricing of its $200 million public offering, which is critical for funding the regulatory, manufacturing, and anticipated commercial launch of its lead gene therapy candidate, TSHA-102 for Rett syndrome. This capital raise extends the company's cash runway into the second half of 2028, providing essential resources following recent positive clinical trial news for TSHA-102. However, the offering involves significant dilution for existing shareholders, with up to 13.3% of new shares being issued, and is priced at a discount to the stock's recent trading levels, which may exert downward pressure on the share price in the short term.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TSHA was trading at $6.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.25 to $7.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.